**Appendix Table D109. Effectiveness of specialized pharmaceutical care for migraine compared to standard counseling for migraine prevention in adults (results from low risk of bias randomized controlled clinical trial)215**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Definition of the Outcome** | **Mean [Standard Deviation] with Active Intervention** | **Mean [Standard Deviation] with Control Intervention** | **Mean Difference****(95% CI)** | **Cohen Standardized Mean Difference****(95% CI)** |
| Days/month with headache | 6.1 [6.7] | 6.4 [6.9] | -0.30 (-1.61 to 1.01) | 0.0 (-0.2 to 0.1) |
| Headache attacks/month | 4.6 [6.1] | 5.1 [7.3] | -0.43 (-1.74 to 0.88) | -0.1 (-0.3 to 0.1) |
| Intensity of pain: Untreated (on an analog scale of 1 (no headache) to 10 (extremely intense headache) | 6.8 [3.4] | 7.3 [2.9] | -0.46 (-1.07 to 0.15) | -0.1 (-0.3 to 0.0) |
| Intensity of pain: Treated (on an analog scale of 1 (no headache) to 10 (extremely intense headache) | 3.3 [2.7] | 3.5 [2.8] | -0.19 (-0.73 to 0.35) | -0.1 (-0.3 to 0.1) |
| Self-efficacy (Definitions of Schwarzer et al. Higher the score better the self-efficacy) | 83.8 [7.5] | 84.5 [8.2] | -0.78 (-2.30 to 0.74) | -0.1 (-0.3 to 0.1) |
| Quality of life: physical health (SF-36) | 43.0 [10.3] | 44.4 [9.1] | -1.37 (-3.25 to 0.51) | -0.1 (-0.3 to 0.1) |
| Quality of life: mental health (SF-36) | 49.4 [9.1] | 49.5 [10.4] | -0.09 (-1.98 to 1.80) | 0.0 (-0.2 to 0.2) |